Friday 6 November 2026 Export INSM’s income statement to Excel — free account

Insmed, Inc.

INSM Healthcare Biotechnology

Insmed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.4 million, up 66.7% from fiscal 2024.

Revenue: +268.4%
EPS: +73.8%
Free cash flow: +81.1%
Total debt: +0.27%

Quarter to September 2026, against a year earlier

Revenue growth 5 yrs

113.13 4.37 +4.02%

Follow INSM

Alert me

Market cap: $23.9B
P/E: 0.0×
Fwd P/E: −64.6×
Dividend yield: —
F-score: 4/9
Altman Z: 9.29
Beneish M: −1.90
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Insmed, Inc. 10-Q filed Aug 6, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed Aug 6, 2026 · accepted 6:59 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part II, Item 1A, Risk Factors, against the 10-Q filed May 7, 2026: no changes